国产安吖啶治疗急性白血病Ⅱ期临床试用  

PHASE II TRIAL OF AMSACRINE IN PATIENTS WITH ACUTE LEUKEMIA

作　　者：江滨[1] 王德炳[1] 付剑峰[1] 单福香[1] 李永敢 陆道培[1] 

机构地区：[1]北京医科大学血液病研究所

出　　处：《北京医科大学学报》1993年第5期315-317,共3页Journal of Peking University(Health Sciences)

摘　　要：应用国产安吖啶对11例急性白血病进行诱导缓解化疗,初治6例,复治5例。4例达完全缓解(CR),CR率为36.4％。其中初治者为33.3％(2/6),复治者为40％(2/5)。总有效率45.5％。该药的剂量限制性毒性反应为骨髓抑制,部分病例有肝功能损害。Eleven patients with acute leukemia received remission induction chemotherapy with amsacrine (m-AMSA). Six patients were previously untreated, 2 were in relapse, and 3 were refractory. Four pati-ents (36.4%) reached complete remission (CR). Total response rate is 45.5%. Subset analysis showedthe following CR rates: previously untreated 33.3%, relapsed and primary refractory 40%. The dose-limiting toxicity of m-AMSA is myelosuppression. Another side effect is impairment of hepatic func-tion.

关 键 词：安吖啶 白血病 缓解率 

分 类 号：R733.7[医药卫生—肿瘤]